Key factors
sym | AZN |
exch | US |
MCap | 211.94B |
Beta | 0.19 |
PE Ratio | 35.79 |
EPS | 1.91 |
Div | 2.9 |
Div Yld | 2.119 |
Div date | 2024-02-22 |
Yesterday
sym | AZN |
exch | US |
close | 75.03 |
50 Day MA | 66.07 |
200 Day MA | 66.61 |
52 Week High | 74.90 |
52 Week Low | 59.55 |
Target Price | 81.81 |
Market Cap Mln | 211.94K |
Share statistics
Shares Outstanding | 3.100B |
Shares Float | 1.544B |
Percent Institutions | 16.80 |
PercentInsiders | 0.005 |
SharesShort | 7658.08K |
Short Ratio | 1.61 |
Shares Short Prior Month | 10.48M |
Short Percent | 0.270 |
Income
Revenue TTM | 45.81B |
Revenue Per Share TTM | 2.454 |
Quarterly Revenue Growth YOY | 7.299 |
Gross Profit TTM | 35.73B |
EBITDA | 15.01B |
Diluted Eps TTM | 1.91 |
Quarterly Earnings Growth YOY | 5.900 |
earning
Operating Margin TTM | 0.169 |
PEGRatio | 0.886 |
Trailing PE | 35.79 |
EPS Estimate Current Quarter | 0.79 |
EPS Estimate Current Year | 4.56 |
EPS Estimate Next Quarter | 1.01 |
EPS Estimate Next Year | 5.13 |
Earnings Share | 1.91 |
Dividend
Forward Annual Dividend Rate | 1.45 |
Forward Annual Dividend Yield | 2.119 |
Payout Ratio | 39.84 |
Dividend Date | 2024-03-25 |
Last Split Date | 2015-07-27 |
Last Split Factor | 2:1 |
business
Enterprise Value Ebitda | 17.73 |
Enterprise Value Revenue | 5.197 |
Book Value /share | 25.25 |
Price Book MRQ | 5.459 |
Price Sales TTM | 4.665 |
ProfitMargin | 0.13 |
ReturnOnAssetsTTM | 0.066 |
ReturnOnEquityTTM | 0.156 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Pharmaceuticals |
Gic Sector | Health Care |
Gic Sub Industry | Pharmaceuticals |
Industry | Drug Manufacturers - General |
Sector | Healthcare |
Codes
ISIN | US0463531089 |
Code | AZN |
CUSIP | 046353108 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-04-19 |
Home Category | ADR |
info
Fiscal Year End | December |
ForwardPE | 16.31 |
Full Time Employees | 89900 |
IPODate | 1993-05-12 |
International Domestic | International Domestic |
MostRecent Quarter | 2023-12-31 |
Contact
Name | AstraZeneca PLC ADR |
Address | 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA |
Country Name | USA |
Phone | 44 20 3749 5000 |
Web URL | https://www.astrazeneca.com |
Logo URL | /img/logos/US/azn.png |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.